Generation Bio

Generation Bio EBITDA Growth YoY

Delisted

The Year-over-Year EBITDA Growth of Generation Bio (GBIO) as of Nov 10, 2026 is -2.76 %. In the previous year, Year-over-Year EBITDA Growth was 1.86 % — a change of -248.89% (lower).

EBITDA Growth YoY

-2.76 %

YoY

-248.89%

Last updated:

Year-over-Year EBITDA Growth of Generation Bio is 2024 -2.76 % . Year-over-Year EBITDA Growth of Generation Bio was 2023 1.86 % . It decreases by -248.89% lower compared to the previous year.

The Generation Bio EBITDA Growth YoY history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Growth YoY
Date
EBITDA Growth YoY
Jan 1, 2019
-67.06 USD
Jan 1, 2020
-30.19 USD
Jan 1, 2021
-46.83 USD
Jan 1, 2022
-18.54 USD
Jan 1, 2023
1.86 USD
Jan 1, 2024
-2.76 USD
The Generation Bio EBITDA Growth YoY history
YEAREBITDA Growth YoYYoY
-2.76 %-248.89%
1.86 %-110.01%
-18.54 %-60.41%
-46.83 %+55.10%
-30.19 %-54.97%
-67.06 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Generation Bio Stock analysis

What does Generation Bio do? Generation Bio Co. is a genetic medicines company headquartered in Cambridge, Massachusetts, that focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. The firm is developing a class of gene therapy utilizing its non-viral gene therapy platform to deliver genetic payloads to a range of tissues. The company’s non-viral gene therapy platform includes its DNA construct called closed-ended DNA (ceDNA), its cell-targeted lipid nanoparticle delivery system (ctLNP) and its established, scalable capsid-free manufacturing process. The firm is engineering its gene therapies to be redosable, which enable patient titration to reach the desired therapeutic expression and to maintain efficiency in a patient’s life. The firm is a preclinical stage company and have not identified a product candidate. Generation Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Generation Bio stock

Year-over-Year EBITDA Growth of Generation Bio is -2.76 % in 2024.

On Eulerpool you can find the complete historical development of Year-over-Year EBITDA Growth Generation Bio since 2006 – with annual values, charts, and detailed analysis.

EBITDA growth measures the percentage change in EBITDA compared to the prior year. It shows changes in operating cash earnings before capital structure effects.

To evaluate Year-over-Year EBITDA Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBITDA Growth.

Year-over-Year EBITDA Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBITDA Growth's Generation Bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Generation Bio

All Key Metrics — Generation Bio